ZASOCITINIB
TAK-279-IBD-2001
Phase 2 small_molecule active
Quick answer
ZASOCITINIB for Moderate to Severely Active Ulcerative Colitis & Moderate to Severely Active Crohn's Disease is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Moderate to Severely Active Ulcerative Colitis & Moderate to Severely Active Crohn's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active